S-1/A: Synergy CHC Corp. Files Amendment No. 2 to Form S-1 for Proposed IPO

Synergy CHC Corp. has filed an amendment to its registration statement for a proposed IPO, aiming to list on the Nasdaq Capital Market under the symbol SNYR.

Summary

• Synergy CHC Corp., a provider of consumer health care, beauty, and lifestyle products, has filed Amendment No. 2 to its Form S-1 registration statement.
• The company is planning an IPO and aims to list its common stock on the Nasdaq Capital Market under the symbol SNYR.
• The product portfolio includes FOCUSfactor, a brain health supplement, and Flat Tummy, a lifestyle and wellness brand.
• The company intends to use the net proceeds of this offering for general corporate purposes.
• The company's revenue for the year ended December 31, 2023, was $42.8 million, with a net income of $6.3 million and EBITDA of $10.8 million.
• For the six months ended June 30, 2024, revenue was $17.4 million, with a net income of $1.2 million and EBITDA of $3.5 million.
• The company's officers and directors will hold approximately 61% of the outstanding common stock upon completion of this offering.
• The company plans to expand into Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.
• The company has entered into a loan agreement with Knight Therapeutics, with a total consolidated amount outstanding of $12.3 million as of June 30, 2024, bearing interest at 12% per year.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as revenue growth in 2023 and expansion plans, there are also concerns about working capital deficit, reliance on key customers, and competitive pressures. The recent decrease in revenue and net income for the six months ended June 30, 2024, also contributes to a more cautious outlook.

Positives

• The company has a well-established brand portfolio with FOCUSfactor and Flat Tummy.
• FOCUSfactor is supported by an independent clinical study.
• The company has premier retail partners, including Costco, Walmart, and Amazon.com.
• The company operates with a scalable and flexible asset-light model.
• The company is experiencing growth in the brain health supplement market, which is slated to grow at 8% per year in the United States and 13% per year globally.
• The company has successfully demonstrated the ability to leverage its existing retailer relationships to expand its RTDs.

Negatives

• The company has a working capital deficit of $3.8 million as of June 30, 2024.
• The company is highly levered, with a focus on paying debt.
• The company depends on a small number of large retailers for a significant portion of its sales.
• The company operates in a highly competitive industry.
• The company's sales growth is dependent upon maintaining its relationships with existing customers, and the loss of any one such customer could materially adversely affect our business and financial performance.
• The company's net revenue for the six months ended June 30, 2024 was $17.4 million, a decrease of $1.3 million, or 7.0% over net revenue for the six months ended June 30, 2023.

Risks

• The company operates in a highly competitive industry.
• The company's sales growth is dependent upon maintaining relationships with a small number of existing large customers.
• The company may experience product recalls, withdrawals, or seizures.
• The company is subject to numerous laws and regulations that apply to the manufacturing and sale of nutritional supplements.
• The company's officers and directors have the ability to significantly influence or control matters requiring a stockholder vote.
• The price of the company's common stock may be volatile.
• The company may need to raise additional capital in the future, and its failure to do so could restrict its operations or adversely affect its ability to operate and continue its business.

Future Outlook

The company intends to use the net proceeds of this offering for general corporate purposes and initiatives to accelerate the growth of both FOCUSfactor supplements and FOCUSfactor energy RTD products. The company plans to expand into Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.

Industry Context

The company operates in the growing nutritional supplement market, particularly in the brain health segment, which is expected to grow at 8% per year in the United States and 13% per year globally. The company is also capitalizing on the evolving energy RTD category.

Comparison to Industry Standards

• The document mentions competitors in the energy RTD category such as Celsius, Bang, Reign, and C4, highlighting FOCUSfactor's differentiation through its dual-benefit formula and lower reliance on caffeine.
• The document references Zion Research and Euromonitor data to provide context on the size and growth of the beverage and energy RTD markets, respectively.
• The document mentions Grand View Research to provide context on the size and growth of the brain health supplement market.

Legal Proceedings

• The company settled a lawsuit with Barbara Valenti in December 2022 for $340,000.
• The company settled a lawsuit with HVL, LLC d/b/a Atrium Innovations in December 2023, resulting in a net gain of $2,235,986 and a loan payable of $5,450,000.
• The company settled a claim with L.O.D.C. Group in April 2024.

Related Party Transactions

• The company has a Sales and Marketing Consultant and Distribution Agreement with Kenek Brands Inc., owned by Jack Ross, the Chief Executive Officer.
• The company has a Loan Agreement with Knight Therapeutics (Barbados) Inc., an affiliate of an owner of greater than 10% of the company's outstanding common stock.
• The company has distribution agreements with Knight Therapeutics, Inc. and Knight Therapeutics International S.A. for FOCUSfactor, Hand MD, and Sneaky Vaunt in various territories.
• The company has transactions with BoomBod Ltd., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.
• The company has transactions with Gowan Properties Inc., a related party 100% indirectly owned by Jack Ross, the Chief Executive Officer.

Stakeholder Impact

• Shareholders may experience dilution from future issuances of common stock.
• Employees may benefit from the company's growth strategy and potential for increased compensation and benefits.
• Customers may benefit from new product development and expanded distribution.
• Suppliers may benefit from increased demand for raw materials and manufacturing services.
• Creditors are subject to risks associated with the company's indebtedness.

Next Steps

• The company plans to expand into Taiwan and Mexico markets in the second quarter of 2025 and in Australia and Asia markets in the first quarter of 2026.
• The company anticipates a coordinated expansion of its advertising strategy towards the end of 2024.
• The company intends to introduce three to five new SKUs across three potential retailers, which would potentially result in the addition of approximately 50,000 points of distribution.
• The company will re-launch the RTDs at the end of 2024 through a major retailer.
• The company plans to introduce an additional FOCUSfactor supplement for Taiwan, RTDs for the UK and focus and energy coffee for the United States in 2025.
• The company plans on introducing new complementary products to the Flat Tummy line-up, including new protein shakes, gut-healthy ready-to-drink beverage, hydration powder and pre-workout powder in the fourth quarter of 2024.

Key Dates

Keywords

FOCUSfactor, Flat Tummy, IPO, brain health, nutritional supplements, consumer health care, EBITDA, Nasdaq, SNYR, retail partners